argenex (NASDAQ:ARGX) Price Target Raised to $1,124.00 at Citigroup

argenex (NASDAQ:ARGX) had its price target upped by Citigroup from $1,041.00 to $1,124.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group set a $818.00 price target on argenex and gave the stock a “buy” rating in a report on Tuesday, August 26th. JPMorgan Chase & Co. increased their target price on shares of argenex from $830.00 to $925.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. HC Wainwright lifted their price target on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Zacks Research cut shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Finally, TD Cowen raised their target price on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $903.78.

argenex Stock Performance

argenex stock opened at $929.61 on Monday. The firm has a market cap of $57.24 billion, a price-to-earnings ratio of 39.91, a PEG ratio of 0.93 and a beta of 0.45. argenex has a 52-week low of $510.05 and a 52-week high of $934.13. The firm has a 50 day moving average price of $802.57 and a two-hundred day moving average price of $674.85.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. As a group, equities research analysts predict that argenex will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its position in argenex by 14.8% in the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after purchasing an additional 21,805 shares during the last quarter. Amundi boosted its holdings in shares of argenex by 8.1% in the 1st quarter. Amundi now owns 6,351 shares of the company’s stock worth $3,747,000 after buying an additional 478 shares during the last quarter. Voya Investment Management LLC grew its position in argenex by 5.2% during the first quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock valued at $8,822,000 after buying an additional 735 shares during the period. Royal Bank of Canada raised its position in argenex by 0.9% in the first quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after acquiring an additional 353 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in argenex by 40.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock worth $2,542,000 after acquiring an additional 1,328 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.